Genmab A/S (NASDAQ:GMAB) Cut to “Buy” at Wall Street Zen

Wall Street Zen downgraded shares of Genmab A/S (NASDAQ:GMAB) from a strong-buy rating to a buy rating in a research report released on Saturday.

Several other equities analysts also recently issued reports on GMAB. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Truist Financial raised their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. Zacks Research raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Genmab A/S in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $30.54 on Friday. The company has a market cap of $19.61 billion, a price-to-earnings ratio of 15.35, a PEG ratio of 1.85 and a beta of 0.98. The firm has a 50 day simple moving average of $28.14 and a 200 day simple moving average of $23.47. Genmab A/S has a one year low of $17.24 and a one year high of $33.65.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently bought and sold shares of GMAB. Osaic Holdings Inc. raised its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the period. CWM LLC raised its position in Genmab A/S by 28.3% in the third quarter. CWM LLC now owns 2,306 shares of the company’s stock worth $71,000 after acquiring an additional 509 shares during the period. Captrust Financial Advisors raised its position in shares of Genmab A/S by 2.4% in the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after purchasing an additional 526 shares during the period. Rhumbline Advisers raised its position in shares of Genmab A/S by 3.2% in the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock valued at $332,000 after purchasing an additional 532 shares during the period. Finally, Yousif Capital Management LLC raised its position in shares of Genmab A/S by 7.8% in the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after purchasing an additional 790 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.